Finance

Beta
Lists
TNGX:NASDAQ
Tango Therapeutics Inc
$30.90
+2.52%
(+0.76) 1D
Jun 26, 11:33:09 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNGX...
Open
$31.47
High
$31.50
Low
$30.51
Mkt. cap
5.01B
Avg. vol.
4.99M
Volume
1.98M
52-wk high
$34.39
52-wk low
$4.80
EPS
-$0.83
Beta
1.18
Shares outstanding
162.82M
No. of employees
137
Open
$31.47
High
$31.50
Low
$30.51
Mkt. cap
5.01B
Avg. vol.
4.99M
Volume
1.98M
52-wk high
$34.39
52-wk low
$4.80
EPS
-$0.83
Beta
1.18
Shares outstanding
162.82M
No. of employees
137
News stories
From sources across the web
About Tango Therapeutics Inc
CEO-
Employees137
Founded2017
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitetangotx.com
Analyst ratings
Based on 11 analysts giving stock ratings to TNGX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TNGX in the last 3 months.
Highest
Current $30.90
$66.00 (+113.59%)
Average
$41.64 (+34.76%)
Lowest
$24.00 (-22.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maury Raycroft
Jefferies
Buy
Upgraded
$60.00
+94.2%
06/26/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$32.00
+3.6%
06/09/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$66.00
+113.6%
06/10/2026
John Newman
Canaccord Genuity
Buy
Maintained
$42.00
+35.9%
06/11/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
$36.00
+16.5%
06/08/2026
Kalpit Patel
Wolfe Research
Buy
Upgraded
$35.00
+13.3%
06/08/2026
Yuan Zhi
B. Riley Securities
Buy
Reiterated
$35.00
+13.3%
06/09/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$32.00
+3.6%
06/01/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$40.00
+29.4%
05/25/2026
Kelsey Goodwin
Piper Sandler
Hold
Downgraded
$24.00
-22.3%
05/15/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$55.00
+78%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$33.00
+6.8%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.18M
53.81M
-
-
Cost of goods sold
32.81M
30.82M
32.10M
33.53M
Cost of revenue
32.81M
30.82M
32.10M
33.53M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.34M
8.92M
9.76M
15.24M
Operating expense
11.34M
8.92M
9.76M
15.24M
Total operating expenses
44.15M
39.74M
41.86M
48.77M
Operating income
-40.97M
14.07M
-41.86M
-48.77M
Other non operating income
910.00K
705.00K
3.30M
-45.00K
EBT including unusual items
-38.82M
15.87M
-38.80M
-45.51M
EBT excluding unusual items
-38.82M
15.87M
-36.88M
-46.64M
Income tax expense
35.00K
-10.00K
-55.00K
1.00K
Effective tax rate
-0.09%
-0.06%
0.14%
-
Other operating expenses
-
-
-
-
Net income
-38.85M
15.88M
-38.75M
-45.51M
Net profit margin
-1,221.41%
29.52%
-
-
Earnings per share
-0.35
0.13
-0.29
-0.32
Interest and investment income
1.24M
1.10M
1.68M
2.18M
Interest expense
-
-
-
-
Net interest expenses
1.24M
1.10M
1.68M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.34M
14.63M
-41.38M
-48.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of TNGX
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer